Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD000545.pub4PMID 23633304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Clinical pharmacology and pharmacogenetics of thiopurines

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review

  2008cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine

  2002cited by this paper
• Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. German Imurek Study Group.

  1999cited by this paper
• Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.

  1997cited by this paper
• Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.

  1997cited by this paper
• Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.

  1997cited by this paper
• A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate

  1997cited by this paper
• A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.

  1996cited by this paper
• An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.

  1995cited by this paper
• Reduction in neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease

  1995cited by this paper
• The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease.

  1994cited by this paper
• Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

  1993cited by this paper
• Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease.

  1993cited by this paper
• 6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease.

  1991cited by this paper
• Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease.

  1991cited by this paper
• Use of azathioprine in nine children with Crohn's disease.

  1991cited by this paper
• [Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases].

  1990cited by this paper
• Safety of azathioprine in pregnancy in inflammatory bowel disease.

  1990cited by this paper
• Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism

  1989cited by this paper
• 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.

  1989cited by this paper
• Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.

  1986cited by this paper
• Long-term immunosuppressive treatment in Crohn's disease.

  1985cited by this paper
• Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

  1983cited by this paper
• Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial.

  1981cited by this paper
• Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

  1980cited by this paper
• Clinical features and natural history of Crohn's disease.

  1979cited by this paper
• National Cooperative Crohn's Disease Study: adverse reactions to study drugs.

  1979cited by this paper
• National Cooperative Crohn's Disease Study: study design and conduct of the study.

  1979cited by this paper
• National Cooperative Crohn's Disease Study: results of drug treatment.

  1979cited by this paper
• Place of azathioprine for Crohn's disease.

  1976cited by this paper
• Treatment of Crohn's disease with azathioprine: a controlled evaluation.

  1974cited by this paper
• Azathioprine treatment in Crohn's disease.

  1974cited by this paper
• Azathioprine therapy for Crohn's disease.

  1972cited by this paper
• Azathioprine in acute Crohn's disease.

  1972cited by this paper
• Azathioprine in the Treatment of Crohn's Disease

  1972cited by this paper
• Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis

  1971cited by this paper
• Azathioprine: An Adjunct to Surgical Therapy of Granulomatous Enteritis

  1970cited by this paper
• Azathioprine therapy for inflammatory bowel disease. A preliminary report.

  1970cited by this paper
• Further experience with azathioprine for Crohn's disease.

  1970cited by this paper
• Azathioprine for Crohn's disease.

  1969cited by this paper

• Understanding the therapeutic toolkit for inflammatory bowel disease

  2025cites this paper
• Chirurgie des complications anorectales de la maladie de Crohn

  2025cites this paper
• Cirugía de las complicaciones anorrectales de la enfermedad de Crohn

  2025cites this paper
• British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

  2025cites this paper
• ACG Clinical Guideline: Management of Crohn's Disease in Adults

  2025cites this paper
• Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses

  2025cites this paper
• Immunomodulators and Advanced Therapies for Induction of Remission in Crohn’s Disease: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• Revolutionizing IBD therapy: Insights into contemporary treatment strategies

  2025cites this paper
• Nanoparticle-Mediated Ferroptosis for Cancer Therapy: Mechanisms and Therapeutic Strategies

  2025cites this paper
• Ferroptosis in Cancer and Inflammatory Diseases: Mechanisms and Therapeutic Implications

  2025cites this paper
• Chirurgia per le complicanze ano-rettali della malattia di Crohn

  2025cites this paper
• Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study

  2024cites this paper
• Medical management of pediatric inflammatory bowel disease.

  2024cites this paper
• Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis

  2024cites this paper
• Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation

  2024cites this paper
• Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline

  2024cites this paper
• Therapeutic Agents and Patient Characteristics Affecting Metabolism of Thiopurines in Patients with Inflammatory Bowel Disease

  2024cites this paper
• Meta-analysis of the human gut microbiome uncovers shared and distinct microbial signatures between diseases

  2024cites this paper
• Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease

  2024cites this paper
• Professional Nursing Care Applied to The Individual Diagnosed with Crohn's Disease: A Case Report

  2024cites this paper
• The Fundamentals of Inflammatory Bowel Disease Management in Pregnancy: A Practical Review for the Gastroenterologist

  2024cites this paper
• Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment

  2024cites this paper
• Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-Severe Ulcerative Colitis: A Prospective Multicenter Cohort (MOSAIK) Study.

  2024cites this paper
• Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents

  2024cites this paper
• IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction

  2024influential citation
• Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn’s disease severity

  2024cites this paper
• Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023

  2024cites this paper
• Ferroptosis in glioma therapy: advancements in sensitizing strategies and the complex tumor-promoting roles.

  2024cites this paper
• Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review

  2023cites this paper
• Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: a systematic review and network meta-analysis

  2023cites this paper
• Pediatric IBD patients show medication and disease activity dependent changes in NK cell and CD4 memory T cell populations

  2023cites this paper
• NUDT15 Haplotypes and Diplotypes Predict Thiopurine‐Induced Leukopenia and the Influence of Prolonged Exposure to Azathioprine on Hematologic Indices in Patients with Inflammatory Bowel Diseases

  2023cites this paper
• Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?

  2023cites this paper
• Long‐term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real‐world experience

  2023cites this paper
• Immunosuppressants

  2022cites this paper
• Immunomodulators: still having a role?

  2022cites this paper
• Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilization in Singapore

  2022cites this paper
• Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial

  2022cites this paper
• Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

  2022cites this paper
• Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress

  2022cites this paper
• The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD.

  2022cites this paper
• Conventional Therapies for Crohn's Disease.

  2022cites this paper
• Parenteral Methotrexate Is Efficient in the Treatment of Azathioprine Refractory Crohn's Disease.

  2022cites this paper
• Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease

  2022cites this paper
• Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies

  2021cites this paper
• Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

  2021cites this paper
• Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment

  2021cites this paper
• 25 years of biologicals in IBD: What´s all the hype about?

  2021cites this paper
• Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators

  2021cites this paper
• Biomarkers for gastrointestinal adverse events related to thiopurine therapy

  2021cites this paper
• Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases

  2021cites this paper
• Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease

  2021cites this paper
• Management of Crohn Disease-Reply.

  2021cites this paper
• Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

  2021cites this paper
• Use of thiopurines in inflammatory bowel disease: an update

  2021cites this paper
• Twenty‐five years of biologicals in IBD: What´s all the hype about?

  2021cites this paper
• Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease

  2021cites this paper
• Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease

  2021cites this paper
• Effectiveness and safety of methotrexate monotherapy in patients with Crohn’s disease refractory to anti‐TNF‐α: results from the ENEIDA registry

  2021cites this paper
• Recent Advances in Diagnosis and Management of Crohn’s Disease

  2021cites this paper
• Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis

  2021cites this paper
• Crohn's Disease

  2020cites this paper
• Positioning Therapies in the Management of Crohn's Disease.

  2020cites this paper
• Current review of the management of fistulising perianal Crohn’s disease

  2020cites this paper
• Part I: Inflammatory bowel disease

  2020cites this paper
• Anti-MAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn’s Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection

  2020cites this paper
• Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn’s disease

  2020cites this paper
• The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update.

  2020cites this paper
• Recommendations of the Crohn’s Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn’s disease

  2020cites this paper
• Nonbiologic Immune Suppression in Ulcerative Colitis.

  2020cites this paper
• Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease

  2020cites this paper
• A rare case of Azathioprine-induced leukopenia in an European woman

  2020cites this paper
• Inflammatory bowel disease and targeted oral anti-TNFα therapy.

  2020cites this paper
• Inflammatory Bowel Disease - non-biological treatment.

  2020cites this paper
• Porous graphitic carbon based chromatography hyphenated with mass spectrometry: A new strategy for profiling thiopurine nucleotides in patients with inflammatory bowel diseases.

  2020cites this paper
• The historical role and contemporary use of corticosteroids in inflammatory bowel disease.

  2020cites this paper
• The Kock Pouch

  2019cites this paper
• Prediction of Thiopurine Metabolite Levels Based on Hematological and Biochemical Parameters.

  2019cites this paper
• Thiopurines with low-dose allopurinol (ThiLDA)—a prospective clinical one-way crossover trial

  2019cites this paper
• Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.

  2019cites this paper
• Recent Progress in Ferroptosis Inducers for Cancer Therapy

  2019cites this paper
• Clematichinenoside AR ameliorated spontaneous colitis in Il-10-/- mice associated with improving the intestinal barrier function and abnormal immune responses.

  2019cites this paper
• The mouth in inflammatory bowel disease and aspects of orofacial granulomatosis.

  2019cites this paper
• Recent advances in the management of perianal fistulizing Crohn’s disease: lessons for the clinic

  2019cites this paper
• Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies

  2019cites this paper
• Traditional Chinese medicine for management of recurrent and refractory Crohn disease

  2019cites this paper
• Importance of 6-Thioguanine Nucleotide Metabolite Monitoring in Inflammatory Bowel Disease Patients Treated with Azathioprine

  2019cites this paper
• Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries

  2019cites this paper
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.

  2019cites this paper
• Crohn’s disease: Current approaches in the management and remission

  2019cites this paper
• Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants

  2019cites this paper
• Clinical Practice Guideline for the Management of Luminal Crohn's Disease: The Toronto Consensus.

  2019cites this paper
• The Evolving Role of Thiopurines in Inflammatory Bowel Disease

  2019cites this paper
• The Evolving Role of Thiopurines in Inflammatory Bowel Disease

  2019cites this paper
• Biologics versus Immunomodulators or Antibiotics for the Management of Fistulizing Crohn’s Disease: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness

  2019cites this paper
• Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.

  2019cites this paper
• Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring

  2018cites this paper
• Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track

  2018cites this paper
• ACG Clinical Guideline: Management of Crohn’s Disease in Adults

  2018cites this paper
• Crohn's Disease: Diagnosis and Management.

  2018cites this paper